Amneal Pharmaceuticals General and Administrative Expenses 2011-2026 | AMRX

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Amneal Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
527 M	476 M	430 M	400 M	366 M	327 M	290 M	230 M	109 M	119 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
527 M	109 M	327 M

Quarterly General and Administrative Expenses Amneal Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
138 M	124 M	118 M	119 M	116 M	113 M	113 M	106 M	102 M	-	100 M	98.8 M	98.7 M	-	91.4 M	86.2 M	90.7 M	-	83.1 M	80.9 M	78 M	-	63.8 M	67.3 M	84.4 M	-	75.5 M	56 M	25.1 M	-	27.4 M	26.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
138 M	25.1 M	87.8 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	14 B	$ 212.08	0.45 %	$ 375 B	USA
AbCellera Biologics ABCL	83.2 M	$ 3.29	-1.94 %	$ 983 M	Canada
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	10.9 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	72.7 M	$ 12.29	-11.96 %	$ 1.86 B	USA
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	27.8 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	232 K	$ 1.08	-1.38 %	$ 22.2 M	Israel
Enochian Biosciences ENOB	17.9 M	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Summit Therapeutics SMMT	557 M	$ 16.55	-4.11 %	$ 12.4 B	Britain
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
Alnylam Pharmaceuticals ALNY	1.21 B	$ 319.85	-2.53 %	$ 41.9 B	USA
Arbutus Biopharma Corporation ABUS	15.9 M	$ 4.34	-2.47 %	$ 832 M	Canada
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Freeline Therapeutics Holdings plc FRLN	44.6 M	-	-	$ 384 M	Britain
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	20.9 M	-	-10.95 %	$ 876 K	USA
Fusion Pharmaceuticals FUSN	31.2 M	-	-	$ 1.41 B	Canada